AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

MDGL · NASDAQ · Biotechnology

Madrigal Pharmaceuticals (MDGL)

Commercializes Rezdiffra and develops combination therapies for MASH.

$511.30

vs last close−7.53 (−1.45%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	0	0	0	15	62	103	137	213	287	321	311	364
Cost of revenue	0	0	0	1	2	3	5	9	18	24	27	40
Gross profit	0	0	0	14	60	100	133	204	269	297	284	324
	99	117	152	177	176	167	212	251	383	356	377	381
Research & development	71	71	71	71	69	26	44	54	174	116	109	91
	28	47	81	105	108	141	168	197	209	240	269	289
General & administrative	28	47	0	0	108	0	0	0	209	0	0	0
Operating income	−99	−117	−152	−163	−116	−67	−79	−47	−114	−60	−93	−56
	0	5	4	11	9	8	6	5	0	1	−2	−2
Interest income	3	9	8	14	13	11	9	8	10	9	8	7
Interest expense	4	4	4	4	4	3	3	3	7	8	8	−8
Other non-operating income	−3	−9	−8	−14	−13	−11	−9	−8	−7	−9	−6	0
Income before tax	−99	−112	−148	−152	−107	−59	−73	−42	−114	−59	−94	−58
Net income from continuing operations	−99	−112	−148	−152	−107	−59	−73	−42	−114	−59	−94	−58
Net income	−99	−112	−148	−152	−107	−59	−73	−42	−114	−59	−94	−58
EPS, basic	−$5.34	−$5.68	−$7.38	−$7.10	−$4.92	−$2.71	−$3.32	−$1.90	−$5.08	−$2.57	−$3.25	−$1.99
EPS, diluted	−$5.34	−$5.68	−$7.38	−$7.10	−$4.92	−$2.71	−$3.32	−$1.90	−$5.08	−$2.57	−$3.25	−$1.99
Weighted average shares, basic	18	20	20	21	22	22	22	22	22	22	29	29
Weighted average shares, diluted	18	20	20	21	22	22	22	22	22	22	29	29
EBITDA	−95	−108	−144	−148	−103	−56	−70	−39	−106	−50	−86	−56
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	−95	−108	−144	−148	−103	−56	−70	−39	−107	−50	−87	−56